Sökning: onr:"swepub:oai:gup.ub.gu.se/291667" > Effect of Dapaglifl...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06168naa a2200733 4500 | |
001 | oai:gup.ub.gu.se/291667 | |
003 | SwePub | |
008 | 240528s2020 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/2916672 URI |
024 | 7 | a https://doi.org/10.1001/jama.2020.19062 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Petrie, Mark C4 aut |
245 | 1 0 | a Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. |
264 | 1 | b American Medical Association (AMA),c 2020 |
520 | a Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes.To evaluate the effects of dapagliflozin in patients with HFrEF with and without diabetes.Exploratory analysis of a phase 3 randomized trial conducted at 410 sites in 20 countries. Patients with New York Heart Association classification II to IV with an ejection fraction less than or equal to 40% and elevated plasma N-terminal pro B-type natriuretic peptide were enrolled between February 15, 2017, and August 17, 2018, with final follow-up on June 6, 2019.Addition of once-daily 10 mg of dapagliflozin or placebo to recommended therapy.The primary outcome was the composite of an episode of worsening heart failure or cardiovascular death. This outcome was analyzed by baseline diabetes status and, in patients without diabetes, by glycated hemoglobin level less than 5.7% vs greater than or equal to 5.7%.Among 4744 patients randomized (mean age, 66 years; 1109 [23%] women; 2605 [55%] without diabetes), 4742 completed the trial. Among participants without diabetes, the primary outcome occurred in 171 of 1298 (13.2%) in the dapagliflozin group and 231 of 1307 (17.7%) in the placebo group (hazard ratio, 0.73 [95% CI, 0.60-0.88]). In patients with diabetes, the primary outcome occurred in 215 of 1075 (20.0%) in the dapagliflozin group and 271 of 1064 (25.5%) in the placebo group (hazard ratio, 0.75 [95% CI, 0.63-0.90]) (P value for interaction=.80). Among patients without diabetes and a glycated hemoglobin level less than 5.7%, the primary outcome occurred in 53 of 438 patients (12.1%) in the dapagliflozin group and 71 of 419 (16.9%) in the placebo group (hazard ratio, 0.67 [95% CI, 0.47-0.96]). In patients with a glycated hemoglobin of at least 5.7%, the primary outcome occurred in 118 of 860 patients (13.7%) in the dapagliflozin group and 160 of 888 (18.0%) in the placebo group (hazard ratio, 0.74 [95% CI, 0.59-0.94]) (P value for interaction=.72). Volume depletion was reported as an adverse event in 7.3% of patients in the dapagliflozin group and 6.1% in the placebo group among patients without diabetes and in 7.8% of patients in the dapagliflozin group and 7.8% in the placebo group among patients with diabetes. A kidney adverse event was reported in 4.8% of patients in the dapagliflozin group and 6.0% in the placebo group among patients without diabetes and in 8.5% of patients in the dapagliflozin group and 8.7% in the placebo group among patients with diabetes.In this exploratory analysis of a randomized trial of patients with HFrEF, dapagliflozin compared with placebo, when added to recommended therapy, significantly reduced the risk of worsening heart failure or cardiovascular death independently of diabetes status.ClinicalTrials.gov Identifier: NCT03036124. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
700 | 1 | a Verma, Sudodh4 aut |
700 | 1 | a Docherty, Kieran F4 aut |
700 | 1 | a Inzucchi, Solvio E4 aut |
700 | 1 | a Anand, Inder4 aut |
700 | 1 | a Belohlávek, Jan4 aut |
700 | 1 | a Böhm, Michael4 aut |
700 | 1 | a Chiang, Chern-En4 aut |
700 | 1 | a Chopra, Vijay K4 aut |
700 | 1 | a de Boer, Rudolf A4 aut |
700 | 1 | a Desai, Akshay S4 aut |
700 | 1 | a Diez, Mirta4 aut |
700 | 1 | a Drozdz, Jaroslaw4 aut |
700 | 1 | a Dukát, Andre4 aut |
700 | 1 | a Ge, Junbo4 aut |
700 | 1 | a Howlett, Johathan4 aut |
700 | 1 | a Katova, Tzvetana4 aut |
700 | 1 | a Kitakaze, Masafumi4 aut |
700 | 1 | a Ljungman, Charlotta,d 1977u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xljcha |
700 | 1 | a Merkely, Béla4 aut |
700 | 1 | a Nicolau, Jose C4 aut |
700 | 1 | a O´Meara, Eileen4 aut |
700 | 1 | a Vinh, Pham Nguyen4 aut |
700 | 1 | a Schou, Morten4 aut |
700 | 1 | a Tereshechenko, SErgey4 aut |
700 | 1 | a Köber, Lars4 aut |
700 | 1 | a Kosiborod, Mikhail N4 aut |
700 | 1 | a Langkilde, Anna Maria,d 19554 aut |
700 | 1 | a Martinez, Felipe A4 aut |
700 | 1 | a Ponikowski, Piotr4 aut |
700 | 1 | a Sabatine, Marc S4 aut |
700 | 1 | a Sjöstrand, Mikaela,d 1964u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xsjomi |
700 | 1 | a Solomon, Scott D4 aut |
700 | 1 | a Johanson, Per4 aut |
700 | 1 | a Greasley, Peter4 aut |
700 | 1 | a Boulton, David4 aut |
700 | 1 | a Bengtsson, Olof4 aut |
700 | 1 | a Jhund, Pardeep S4 aut |
700 | 1 | a McMurray, John J V4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för medicin, avdelningen för molekylär och klinisk medicin4 org |
773 | 0 | t JAMAd : American Medical Association (AMA)g 323:14, s. 1353-1368q 323:14<1353-1368x 1538-3598x 0098-7484 |
856 | 4 | u https://jamanetwork.com/journals/jama/articlepdf/2763950/jama_petrie_2020_oi_200021_1617397932.1056.pdf |
856 | 4 8 | u https://gup.ub.gu.se/publication/291667 |
856 | 4 8 | u https://doi.org/10.1001/jama.2020.1906 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.